Introduction
Gout is the most common inflammatory arthritis (1) in the US and in many developed countries worldwide (2) , and is linked with multiple serious comorbidities (3) (4) (5) . Acute gout flares (1) are characteristically excruciatingly painful (6) , and are associated with poor health-related quality of life, hospitalization, emergency room visits, and increased health care costs (7) (8) (9) (10) . Despite advancements in the understanding of the pathogenesis and outcomes of gout, the quality of gout care delivered to patients, let alone accepted by them, remains remarkably suboptimal worldwide (11, 12) . To that effect, gout is an inflammatory condition well suited for a straightforward quality improvement framework, in that there is a simple measure for monitoring quality of care (i.e., measurement of serum uric acid [SUA] levels), and robust and pragmatic management guidelines have been published (1, 13, 14) . Moreover, via advances in genomics and in the understanding of molecular pathogenic mechanisms, as summarized in this review, gout care providers in clinical practice are well positioned to take advantage of the emerging transformation of medical care by precision medicine through increased utilization of genomics and other "omics" fields of study.
Key approaches to markedly improving the quality of gout care clearly start with provider and patient education, individualized lifestyle interventions and pharmacologic measures, and the ability to overcome therapeutic inertia (i.e., failure to initiate or intensify treatment in a patient not yet at the evidence-based treatment target) (11, 15) . Such measures in patients with gout closely parallel those in other chronic conditions, such as diabetes and hypertension, for which the time recommended to achieve the therapy target, and individualization of the effort to achieve standard therapy targets, have been extensively investigated and reviewed. In the current review, we look beyond these charted paths, to propose a roadmap for how we can improve the global outcomes of gout in patients by venturing beyond the currently established generation of treatment measures and targets (Table 1) . In doing so, we particularly elaborate on the need to better develop and employ precision medicine approaches and effective implementation strategies to achieve these goals.
Steps to improving quality of gout care and global outcomes
Step 1: refining the disease stages of gout. Gout has recently been reclassified, with equal weight in diagnostic scoring given to the disease features of palpable tophi, ultrasound findings of a double contour sign, and positive findings of urate crystal deposition on dual-energy computed tomography (DECT) (16) . In this context, novel studies using advanced imaging (ultrasound and DECT), as well as compensated polarized light microscopy, have demonstrated that a substantial fraction of individuals with hyperuricemia (i.e., ;25-40% of individuals, depending on the degree of hyperuricemia and the approach employed for urate crystal detection) have evidence of monosodium urate monohydrate (MSU) crystal deposition without gouty joint symptoms (17) (18) (19) . These data support the concept that there are pathophysiologic stages of hyperuricemia/ gout, as follows: 1) asymptomatic hyperuricemia without MSU crystal deposition; 2) asymptomatic hyperuricemia and MSU crystal deposition; 3) gout (i.e., "symptomatic hyperuricemia with MSU crystal deposition"); and 4) progressively more advanced gout, characterized by formation of tophi, chronic arthritis, and joint damage. A few rare cases of gout appear to vary from this standard sequence of events, presumably for idiosyncratic reasons, but it does not obviate the overall value of this new classification scheme.
In conventional models of gout care utilized to date, the decision to initiate urate-lowering therapy (ULT) has been primarily based on frequent episodes of acute gout flares and the presence of features of advanced chronic gouty arthritis (13) . Overall, this disease definition spectrum has been linked to key gout-related outcomes (20) (Figure 1A ). However, symptomatic gout and asymptomatic hyperuricemia (with or without MSU crystal deposition in the tissue) both appear to have implications well beyond the joint (21-25) ( Figure 1B) .
Hyperuricemia has been potentially linked to worsening of hypertension, the onset and progression of chronic kidney disease (CKD), and insulin resistance and obesity (21) (22) (23) . Furthermore, asymptomatic MSU crystal deposition in the joints was recently reported to be strongly associated with moderate to severe coronary Engage primary care physicians to adapt more effective ambulatory models to initially optimize ULT and to control gouty inflammation; broaden use of allied health professional-run gout clinics that apply highlevel disease education methods for patients artery calcification in patients presenting with non-STsegment elevation acute coronary event (24) . It is conceivable that gout is part of a larger "crystal-forming" diathesis in extracellular matrices. Moreover, intriguingly, negatively birefringent crystals (with features of MSU crystals) have been detected in the coronary arteries of explanted hearts and in resected prostate tissue (25) . Such findings suggest that MSU crystal deposition might directly contribute to focal inflammation at nonarticular sites. It remains unknown whether the simple presence of tissue MSU crystal deposits could be predictive of the ultimate development of clinical gout flares, tophus formation, and joint damage, let alone associated comorbidities ( Figure 1 ). It also remains to be determined whether ULT provides benefits that exceed potential risks among individuals with asymptomatic MSU crystal deposition, for prevention of either articular disease or comorbidities. Studies aimed at carefully assessing the clinical implications of confirmed tissue MSU crystal deposition in asymptomatic hyperuricemia are overdue.
Step 2: improving care for the comorbidities of hyperuricemia and gout. Hyperuricemia and gout are strongly associated with cardiovascular-metabolic-renal comorbidities and their sequelae (e.g., myocardial infarction and premature death) (3) (4) (5) . The causal role of gout and hyperuricemia as they pertain to these outcomes remains unresolved, but recent expansion of genetic discovery through genome-wide association studies (GWAS) has allowed novel modes of testing individual associations for potential causality. Mendelian randomization studies are particularly relevant in the context of the gout-urate-cardiovascular disease links, since they take advantage of random assignment of alleles of an individual's genotype at meiosis, thereby eliminating bias by confounding variables and reverse causation. To date, most such Mendelian randomization studies of genetic linkages with uric acid levels and comorbidities in gout have yielded null findings, suggesting that the associations are noncausal (26, 27) . However, in 2 randomized controlled trials (n 5 30 patients and n 5 60 patients, respectively), among adolescents Figure 1 . Current and future definitions of gout and expanded key outcomes. A, Current definitions of gout and key outcomes are restricted to the presence of symptomatic monosodium urate monohydrate (MSU) crystal deposition and important, but limited, management outcomes. B, Top priorities for future revised definitions of gout will address disease stages in both asymptomatic and symptomatic gout, thereby leading the increasing scope for improved outcomes, both for articular and nonarticular features of the disease.
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DALBETH ET AL with hyperuricemia and a state of prehypertension or stage 1 hypertension, treatment with allopurinol or probenecid was associated with lowered blood pressure (28, 29) , with the magnitude of effect being similar to that of the first-line oral antihypertensive agent, whereas a similarly designed trial among adults (n 5 149 patients) did not demonstrate such a treatment benefit (30) . Importantly, participants in the randomized controlled trials did not have gout (28) (29) (30) ; thus, generalizability of the results remains to be clarified. Regardless of the lingering questions related to causality, the high frequency of major comorbidities and their sequelae in gout requires serious consideration of these issues in gout care, moving beyond simply choosing the appropriate anti-gout therapy to a greater focus on reduction of the overall disease burden of gout. For example, observational studies have suggested that allopurinol initiation is associated with a lower risk of allcause mortality (31, 32) and cardiovascular events (33) . Moreover, use of colchicine in patients with gout has been associated with a lower risk of several cardiovascular events (34, 35) .
Taken together, these findings indicate that the optimal gout-limiting therapy approaches (pharmacologic, diet, and lifestyle measures) would adopt a personalized "treat-to-target" paradigm to reduce both the SUA levels and the cardiovascular-metabolic-renal complications. The low-purine dietary approach to gout is clearly obsolete; it offers limited efficacy, palatability, and sustainability, and promotes increased consumption of refined carbohydrates and saturated fat, which can promote insulin resistance and increased concentrations of plasma glucose, triglycerides, and low-density lipoprotein cholesterol (36) . In contrast, we need to better apply effective dietary approaches in order to both reduce the incidence of cardiovascular-metabolic conditions (including obesity and insulin resistance) and also lower the SUA levels and reduce the risk of incident gout. For example, the Dietary Approaches To Stop Hypertension (DASH) diet, which was associated with a uratelowering effect of ;1.3 mg/dl among those with an SUA level of .7 mg/dl (37), warrants further investigation in patients with gout. Moreover, diets aimed at managing the metabolic syndrome and lowering the glycemic index, which have shown urate-lowering effects (36, 38) , merit further examination in patients with gout. Several ongoing randomized trials examining the effects of urate-lowering drugs on cardiovascular-renal outcomes may help to clarify the potential mechanisms of action of such medications on these outcomes, via their uratelowering and/or antioxidant effects through xanthine oxidase inhibition (23) .
Step 3: implementing precision urate-lowering therapy and optimizing target urate levels. US Food and Drug Administration (FDA)-approved drugs for use as ULT in patients with gout include allopurinol, probenecid, febuxostat, pegloticase, and, in combination with a xanthine oxidase inhibitor (XOI), the uricosuric agent lesinurad. Effective implementation of oral ULT may not be easy to achieve in some clinical practices, due to the need for continuously supervised dose-titration regimens and/or risk management strategies in patients receiving allopurinol or certain potent uricosuric agents. This problem is compounded by the high frequencies of both acute flares and nonadherence to treatment after starting the ULT (1, 13) . A number of ULT drugs are in pipeline development ( Table 2 ). Some of these agents have dual mechanisms for urate lowering, or possess both urate-lowering and antiinflammatory properties. However, for individual patients, we need to better understand which ULT drug should be used first and at what dose, and the best option if the first-line ULT drug fails. A prime example, with a baseline ULT regimen that is well-tolerated but only partially effective, is the decision to switch patients to a different oral ULT drug of the same class (XOI or uricosuric agent), or to add another oral drug in a different class by combining XOI and uricosuric therapy. The cost-effectiveness of selected agents and strategies will need further, rigorous study. Precision medicine is defined as "an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person" (for further details, see http://www.nih.gov/precision-medicine-initiative-cohort-program). An integrated approach for clinical practice that systematically considers both genetic and nongenetic variables is needed. Some elements are now in place or within reach for broader applicability (Table 3) .
With regard to allopurinol therapy for gout, an association between the presence of HLA-B*5801 and a markedly increased risk of severe allopurinol hypersensitivity syndrome (AHS) has been well documented (13, 39, 40) . The HLA-B*5801 linkage with AHS is cogent, given the impact on ULT risk management strategies in racial and ethnic groups of patients who have a relatively high allele prevalence of, and confirmed high (42) . Since the event rate of AHS remained low even in Taiwanese with HLA-B*5801 in a recent prospective cohort analysis (40) , the frontiers of allopurinol risk management will likely include more precise identification of the HLA-B*5801 variants and other complex genotypes potentially associated with a risk of AHS. GWAS have provided new insights into the biologic bases for hyperuricemia and gout on a population level, and such findings may be translated to clinical care as whole-genome sequencing becomes increasingly available (Table 3) . Results of GWAS have highlighted the importance of both extrarenal and renal urate transport (43) (44) (45) . The 2 genes found to be most strongly associated with gout in GWAS are ABCG2 and SLC2A9. ABCG2 encodes ABCG2/BCRP, a high-capacity plasma membrane urate efflux transporter that acts, in part, by promoting renal uric acid excretion, and also, in part, by promoting extrarenal (small intestinal) urate secretion, which consequently promotes uric acid degradation by colonic bacterial uricase (44) . SLC2A9 encodes GLUT9, a transporter that mediates renal urate reabsorption at the proximal tubular cell basolateral membrane (45) . GWAS in which the mechanisms of serum urate regulation were assessed have also identified a suite of other renal urate transporters, including SLC22A12 (encoding URAT1, a transporter that regulates renal urate reabsorption on the proximal tubular cell apical membrane), and other pathways, including the inhibins-activins growth factor system and carbohydrate metabolism pathways. Significantly, some genetic variants associated with hyperuricemia and gout interact with body mass index, and with the consumption of alcohol and sugar (46) .
For precision medicine, genomics analyses of the root cause of hyperuricemia in a patient with gout may allow more selective decision-making about what mechanism of action to target (Table 3) . In particular, it may identify patients who are more likely to respond to uricosuric drugs.
Role of ABCG2 in precision models of hyperuricemia in gout. In clinical practice, the efficacy of allopurinol is primarily limited by frequent underdosing and low adherence. However, some patients are adherent to treatment but do not achieve the SUA target levels, despite receiving adequate doses of allopurinol. Variables such as the baseline SUA level, kidney function, diuretic use, and body size contribute to the allopurinol response (47, 48) .
In addition, at least one common ABCG2 variant, Q141K (encoded by the SNP rs2231142), plays an important role in the allopurinol response (49, 50) . This risk is likely attributable to the observation that ABCG2/BCRP transports allopurinol and its long-lived active metabolite (49, 50) . Q141K, which is associated with ;50% loss of urate transport activity as compared to wild-type ABCG2, may act on drug transport in the liver, and possibly elsewhere, to decrease the urate-lowering response to the drug. The allele frequency of ABCG2 rs2231142 appears to be at least ;10% at the population level in white patients, and is less common in those of African extraction, but is several times more common (i.e., ;25-30% in several studies) in populations of Japanese, Han Chinese, Korean, and Western Polynesian descent (51) . In some cohorts of gout patients of Southeast Asian descent, ;50% of the patients have been reported to carry the ABCG2 Q141K rs2231142 allele. Taken together with the studies of HLA haplotype associations with allopurinol-related adverse events, these discoveries of a quite common ABCG2 gene variation in populations of gout patients provide a clear opportunity to develop personalized models for safe and effective allopurinol dosing (Table 3) .
Impairment of the urate transport function and/ or stability or expression of ABCG2 has additional ramifications in gout precision medicine (Table 3) . Specifically, some of the ABCG2 genotypes identified in genetics studies have been found to be associated with a several-fold increase in the odds ratio for development of gout, suggesting that these findings have a possible future use to help improve the ability to predict the likelihood of incident gout in some individuals with asymptomatic hyperuricemia. Furthermore, genotypes that encode for increasing loss of ABCG2 are associated not only with a proportionately earlier onset of gout (a potential biomarker for earlier ULT intervention) (52), but also with extrarenal underexcretion of uric acid, and consequently a condition of "renal uric acid overload, without uric acid overproduction" (44), a phenotype that contraindicates the use of primary uricosuric monotherapy due to the risk of urolithiasis. In this context, carriage of the ABCG2 variant Q126X (encoded by SNP rs72552713), which is entirely nonfunctional for urate transport, is a particularly strong contributor to the phenotype of intestinal underexcretion of urate with renal uric acid overload (44) . Although the presence of Q126X has not been reported in populations of white or black patients, it is relatively common in Japanese subjects (2.4%), and has also been reported in some cohorts of Han Chinese and Korean descent, but at a lower allele frequency (51) .
Collectively, the new findings with regard to the role of ABCG2 have also changed the way we classify causative factors for hyperuricemia in gout, adding renal uric acid overload due to intestinal ABCG2 dysfunction as a factor in addition to uric acid underexcretion and uric acid overproduction (44) . Moreover, the ability to pharmacologically increase ABCG2 function potentially provides a rational target for next-generation ULT agents (53) . Clearly, in the larger population of gout patients, more studies will be needed to integrate data on genomic effects in conjunction with acquired effects on urate transport, together with data on acquired renal comorbidities (e.g., hypertension, CKD) and environmental exposures (i.e., medications, diet, alcohol use, lifestyle) and other factors (Table 3 ). In addition, "omics" approaches other than genomics (e.g., transcriptomics, proteomics, and epigenetic studies [gene methylation, microRNAs]) as well as serum biomarker studies could be important to help advance translation of the molecular pathogenic mechanisms of gout.
How current treat-to-target paradigms are anticipated to evolve. Not all patients with gout require pharmacologic ULT. In those who do (13), current treat-totarget ULT paradigms advocated by rheumatology guidelines recommend an SUA target level of ,6.0 mg/ dl for most patients with gout, and ,5.0 mg/dl for those with "advanced gout," along with evidence of a high body tissue burden of uric acid, such as the presence of palpable tophi, or clinical or imaging evidence of tophaceous disease with joint damage. Unequivocally, more intensive ULT leads to faster dissolution of MSU crystals and regression of tophi (54, 55) . As such, there is potential for more precision in SUA target levels based on the individual clinical presentation, as proposed in Table 4 , although exact numeric SUA targets would need more clinical investigation to validate.
Going forward, we expect to increasingly employ combination therapy with XOI and uricosuric ULT to achieve lower SUA target levels in higher proportions of gout patients who are refractory to simple ULT monotherapy regimens in which appropriate dosing is utilized (13) . Moreover, we need to better define the proportion of gout patients who are truly refractory to simple ULT monotherapy, as opposed to being nonadherent or receiving inappropriate ULT dosing. One unmet need, for those with severe, advanced tophaceous gouty arthritis (13) , is the need to develop less immunogenic dosing regimens and the need to develop other approaches for delivery of recombinant PEGylated uricase, particularly in patients with moderate to severe CKD (Table 2) . Central to progress in the field will be integrative analyses of clinical trials, using both patient-reported outcomes and objective assessments of the crystal burden (e.g., by DECT) as outcome measures. In this way, we can identify optimal SUA target levels for specific clinical presentations (see Table 4 for some of the potential target levels proposed).
In addition, there is the possibility of adjusting an individual patient's SUA target level over time, depending on the initial response of hyperuricemia to treatment. Determining exactly how low to drop the SUA level in each patient may involve not only a question of what level is sufficient to attenuate the gouty inflammation, but also, potentially, a question of whether lowering the levels too much might adversely affect other conditions. These are areas that need substantial further investigation.
Step 4: developing novel prognostic markers and disease activity indices beyond SUA levels. Currently, the levels of SUA, frequent acute gout flare activity, presence of palpable tophi and gouty erosions, definition of a state of uric acid overproduction, urolithiasis, and CKD are the major features of disease activity that help guide the treatment decisions to initiate or intensify ULT and/or prolonged antiinflammatory prophylactic treatment for flare (1, 13) . Higher SUA levels and longer disease duration are associated with an elevated risk of acute gout flares, but there is sizable variability in the risk determined by other factors. Similarly, aside from CKD and disease duration, the factors contributing to a clinical presentation that includes palpable tophi are poorly understood.
The concept of composite disease activity scoring for gout has evolved from early efforts that were simply based on single clinical and laboratory parameters. In light of this, the first gout disease activity scoring system was recently reported, incorporating a 12-month flare count, SUA levels, visual analog scale (VAS) scores for pain, VAS scores for global assessment of disease activity, swollen and tender joint counts, and a cumulative measure of palpable tophi (56) . However, validation of this type of gout disease activity measure is far behind the instruments used for scoring of rheumatoid arthritis and certain other rheumatic diseases. Markers from advanced imaging, such as subclinical (and nonradiographic) synovitis, tophi, and joint damage, have substantial potential for advancing the identification of patients at risk for recurrent flares, tophi, or progressive connective tissue destruction. However, large-scale, wellcharacterized prospective follow-up studies are needed to further identify reliable prognostic markers (both clinical and laboratory, as well as imaging) for the development of disease flares and destructive tophi in patients with gout.
Rapidly emerging knowledge of the molecular cascade of the acute MSU crystal inflammatory response, as well as the priming and master regulatory inhibitory effects in this process, have provided opportunities to identify several new gout inflammation biomarkers (Figure 2) . In this context, gouty inflammation is driven by innate immune responses to MSU crystals. Such core responses include "first signal" priming of the NLRP3 inflammasome in macrophage lineage cells by C5a (via cleavage of C5 on the MSU crystal surface), granulocyte-macrophage colony-stimulating factor, and a variety of Toll-like receptor 2 (TLR-2) and TLR-4 ligands (including the longchain fatty acid palmitate) (57) . MSU crystals provide a "second signal" via NLRP3 inflammasome activation, thereby driving maturational processing and secretion of interleukin-1b (IL-1b) (58) (59) (60) . Local activation of endothelial and mast cells, the ingress and activation of monocytes and neutrophils, and multiple additional cytokines and inflammatory mediators contribute to the full phenotypic expression of the acute gouty arthritis cascade (Figure 2) .
In human serum, the most consistent inflammatory cytokine biomarker in both acute flares and intercritical gout (i.e., between flares) has been reported to be IL-8/ CXCL8, linked to circulating S100A8/A9, a heterodimer robustly released from granules by activated neutrophils (61) . New biomarkers for arthritis activity and disease progression in gout could be mined from processes mediating the constitutive "master" limitation of inflammatory responses to MSU crystals, which also provide potential novel therapy targets, as discussed below for AMPactivated protein kinase (AMPK) and peroxisome proliferator-activated receptor g (PPARg) (Figure 2 ). Other biomarkers and/or therapy targets could include kinins (subject to regulation by angiotensin-converting enzyme inhibitors) (62), C5/C5a (63), and products of MSU crystal inflammation-associated connective tissue turnover.
Step 5: developing novel mechanism-based precision medicine for gouty inflammation. The unmet need for new, safe, and effective antiinflammatory drug options to prevent and treat gouty arthritis is substantial. First, current antiinflammatory gout prophylaxis is dated and imperfect; all first-line oral pharmacologic approaches (low doses of colchicine, nonsteroidal antiinflammatory drugs [NSAIDs] , and corticosteroids) are limited by the potential toxic effects of these drugs, drug-drug interactions (64) , and gaps in therapeutic efficacy (1) . These issues contribute to the frequent preference of patients and clinicians to forego the current generation of pharmacologic prophylactic treatments for flare.
Second, collective randomized, controlled, doubleblind clinical trials of monotherapy for acute gout flares, using the current FDA-approved oral agent standards for patient self-treatment regimens (1), have demonstrated that there is a substantial unmet need (65) . For example, treatment with high-dose or low-dose oral colchicine for early acute gout flare (administered within 12 hours of flare onset) led to only 32.7% of subjects in the high-dose group and 37.8% of subjects in the low-dose group achieving a $50% reduction in flare by 24 hours from baseline, compared to 15.5% of patients in the placebo group, without the need for rescue medication (66) . In addition, in trials with NSAIDs and oral corticosteroids for acute gout flare, including recent trials in which the equivalence of both options was suggested (67), only ;50% of subjects experienced a .50% reduction in flare pain by 72 hours from baseline (65) . Fortunately, studies of combination therapy for flares, although more difficult to design and perform, have retained some promise for improved outcomes (1). Although selective biologic IL-1b inhibition can be effective in preventing and treating gouty joint inflammation (1), it adds substantial cost to treatment regimens, and is not currently FDA-approved.
Precision medicine, and the associated development of new rational therapeutics for gouty arthritis, could also mine its decision-making data not only from the recently identified host processes that limit MSU crystal-induced inflammation, but also from exogenous inflammationstimulatory mechanisms (Figure 2) . In this context, sources of variability in the capacity of MSU crystals to cause inflammation appear to include not only genomic variants of inflammatory mediators (68) , but also targetable epigenetic regulatory effects (e.g., exerted by microRNAs 146a and 155 [69, 70] and by certain class I histone deacetylases [HDACs] [71] ). In this context, the gut microbiome in patients with gout, compared to controls, has been reported to have not only decreased uric acid-degrading capacity, but also decreased potential for generating antiinflammatory effects via biosynthesis of butyrate (72) , which acts partly via HDAC inhibition (71) . Moreover, elevation in the SUA levels itself may have priming effects on macrophage activation, mediated by the suppression of IL-1 receptor antagonist expression via modulation of histone methylation (73) .
Constitutive "master" limitation of host inflammatory responses to MSU crystals also is exerted, in part, by biosensing of changes in nutrition, metabolism, and cellular energy processes, via changes in PPARg signaling (74) , macrophage autophagy (75) , and AMPK activity (76) .
First, in this context, signaling by PPARg, which regulates insulin sensitivity, also limits experimental gouty inflammation. Treatment of patients with a partial PPARg agonist that has additional moderate uricosuric activity (via inhibition of urate transporter 1) demonstrated positive effects in the prevention of gout flare in patients who were evaluated in a phase II clinical trial (74) .
Second, macrophage autophagy, which is promoted under conditions of nutrient deprivation, functions homeostatically in intracellular energy-generating proteostasis by recycling obsolete moieties, including damaged long-lived proteins and organelles. In addition, autophagy plays a major role in maintaining the balance of innate inflammatory processes (75) . Third, constitutive and pharmacologically induced activation of AMPK limits innate inflammation by suppressing NF-kB transcription factor activation (itself a master regulator of inflammation), and also has effects on macrophage differentiation, including promotion of autophagy and antiinflammatory M2 macrophage polarization (76) . AMPK is activated by factors that increase the cellular AMP:ATP ratio (e.g., caloric deprivation, exercise). Conversely, numerous factors that promote gouty inflammation inhibit tissue AMPK activity, exemplified by the effects of intake of palmitate (57) or fructose, other nutritional excesses, excessive alcohol consumption, and also cell stimulation by IL-1b, tumor necrosis factor, and MSU crystals.
Tissue AMPK activity is diminished in obesity, type II diabetes, and metabolic syndrome with linked low-grade adipose tissue inflammation. Moreover, decreased tissue AMPK activity can promote certain comorbidities prevalent in patients with gout, including hypertension, onset and progression of renal disease and associated fibrosis, nonalcoholic steatohepatitis, and atherosclerosis and cardiac hypertrophy (77, 78) . Furthermore, activated AMPK transduces the multiple antiinflammatory effects of colchicine (76) . Significantly, systemic activation of AMPK is induced by certain drugs already being utilized in the clinic for treatment of arthritis and other diseases (e.g., metformin, methotrexate, nonacetylated salicylates, high-dose aspirin). It would be of interest to discern the impact of such agents on gout flares, since some are already commonly employed for comorbidities in patients with gout.
Neutrophil activation is both a major driver and proresolving component in gouty inflammation, since selflimitation of typical gout-like inflammation involves several phagocyte-driven native-resolution mechanisms for acute neutrophilic inflammation (58, 63, 79, 80) (Figure 2 ). These pathways include neutrophil microvesicle release, which inhibits C5a (63), phagocyte ingestion of apoptotic neutrophils, which leads to an altered profile of inflammatory and antiinflammatory mediators released by effector cells (79) , and NETosis, which also may promote tophus development (80) . As such, new candidates for targeting gouty inflammation could emerge from refinements to currently approved modes of modulation of phagocyte activation (by colchicine, NSAIDs, corticosteroids, adrenocorticotropic hormone therapy) in gout. In addition, the identification of IL-37 as one of the antiinflammatory cytokines potentially active in limiting gouty arthritis is noteworthy and merits further investigation (81).
Step 6: improving gout care in all clinical practices, particularly in the primary care setting. While the exact proportion of patients with gout who meet the current indication for urate-lowering drugs is unknown, only 32% of gout patients in the US have been treated with a uratelowering drug (12) . Furthermore, the majority of those receiving urate-lowering drugs are not at SUA target levels (12) , which promulgates poor outcomes (e.g., acute gout flares, including those leading to hospitalization for gout [9] , and joint damage). For example, a recent national study found that primary hospitalization rates for gout have doubled over the past 2 decades in the US, whereas those for rheumatoid arthritis have declined by 67%, owing to improvements in rheumatoid arthritis care (9) . Unequivocally, very few patients with gout in the US receive clear information about the potential to achieve long-term disease remission and, in some cases, a cure for the disease through prolonged treatment with ULT, as has been supported by studies of treatment effects on uric acid pathophysiology (82, 83) . These practices have led to poor medication adherence, with as few as 10% of patients with gout adhering to their treatment (84) .
The current state of suboptimal gout care is promoted, in part, by substantial gaps between rheumatologists and primary care providers in their approaches to gout care and in the guidelines recognized, as was reinforced by the recent review of gout care carried out by the Agency for Healthcare Research and Quality (AHRQ) for the American College of Physicians (85) . In particular, the key approach advocated by rheumatology guidelines for the use of treat-to-target ULT (recommending a minimum SUA target level of ,6.0 mg/dl) has not been implemented as a standard by primary care physicians in gout guidelines and care (85) . This ideological schism between most rheumatologists and primary care physicians (86) is rendered even more vexing given that moderate strength evidence to support the use of ULT for .1 year was recognized by the AHRQ (85) .
Differences in the valuation of long-term ULT in gout may largely be perpetuated by distinct interpretations of the results of relatively short-term (i.e., 6-12 months) randomized controlled phases of clinical trials of oral ULT, which have not routinely shown a reduction in the frequency of gout flare or a resolution of tophi (unlike the later results from subsequent open-label extension periods). Since ;90% of patients with gout receive their care through a primary care physician, we need innovative efforts to systematically improve the outcomes of gout care, including an approach that would intensively engage allied health professionals. Results have been impressive for clinical models that share some aspects of broadly employed management strategies such as anticoagulation and hyperlipidemia therapies and monitoring clinics (87, 88 ). An open-label pilot study conducted at a gout specialty clinic in the UK provided proof-of-concept that remarkable success rates (e.g., 92% achieving SUA levels of ,6 mg/dl and 85% achieving SUA levels of ,5 mg/dl, as well as steadily improving rates of gout flare) can be achieved by implementing a nurse-guided approach that combines patient education, personalized lifestyle measures, and treat-to-target ULT according to rheumatology guidelines, but with patient preferences driving the option of added antiinflammatory prophylaxis (87) . Of the 101 study participants, 21% required an alternative agent for various reasons over 1 year, including only 8% of patients who switched because of treatment failure (87) .
In a US study, a similar strategy of allopurinol treatment in the vast majority of patients with gout, followed by febuxostat treatment in only those patients who showed an inadequate response to allopurinol, was estimated to be cost-effective, based on accepted willingness-to-pay thresholds (89) .
Furthermore, a pharmacist-led US pilot study of ULT in a health maintenance organization setting, conducted under rheumatologists' guidance (88) , provided findings that were somewhat similar to those in the study by Rees et al in the UK (87) . While the emerging pilot data from allied health professional-managed gout clinics are promising, they are derived from open studies (87, 88) . We need more clinical trials, done in a controlled manner, set in different practice environments, and involving patients of different cultural and socioeconomic backgrounds.
Conclusions
Future precision medicine systems that can ultimately lead to improved selection, dosing, safety, efficacy, and cost-effectiveness of the treatments for hyperuricemia in gout should be based on the patient's clinical presentation combined with genomic, environmental, and lifestyle data, should integrate the SUA target level, should take into account the causes of hyperuricemia, and should recognize the predictors of the safety and efficacy of the available therapies. These models need to evolve in step with major upgrades in the number and effectiveness of ULTs and antiinflammatory drug options and regimens. Fortunately, platforms and roadmaps for new models are provided not only by the current research advances in gout inflammation biology, including the recent identification of master regulators and new biomarkers of gouty inflammation, but also by the emerging wealth of new genomics and epigenetic findings applicable to clinical bioinformatics. It is essential that greater attention be paid to integrating better outcomes in gout and the comorbidities of gout. Achieving tighter control of the SUA levels in more patients will be central to this mission. However, major improvements in gout outcomes at a population level will require much deeper engagement of primary care and affiliated health professionals, and will require careful validation, particularly in populations with differing cultural and socioeconomic backgrounds.
